Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI vs FOLFOX Neoadjuvant Therapy for High-Risk Stage III Colon Cancer
ChiCTR2200062808Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of fluorouracil, folinic acid, oxaliplatin and irinotecan in colon cancer (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Down-staging rate and Neoadjuvant toxicity. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecan
03
Conditions
colon cancer
Beyond the preview
Go deeper on ChiCTR2200062808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062808.